19股最新股东户数降逾一成 证券时报·数据宝统计显示，共有390只个股公布了7月20日股东户数，与上期（7月10日）相比，股东户 数下降的有188只。其中股东户数降幅超一成的有19只。 390只股公布截至7月20日最新股东户数，相比上期股东户数下降的有188只，降幅居前的是创益通、汇 中股份、兴森科技等。 股东户数降幅最多的是创益通，截至7月20日最新股东户数为14176户，较7月10日下降27.39%，筹码集 中以来该股累计下跌4.35%，累计换手率为80.16%，其间主力资金净流出2601.85万元。 投资者除了在定期报告中获得股东信息数据外，还可以在交易所互动平台上通过提问方式了解部分公司 更及时（每月10日、20日、月末）的股东户数信息。以往3期分别有789家、738家、809家公司在互动平 台透露了股东户数，截至发稿，共有390家公司公布了截至7月20日股东户数。 上期筹码集中股回测：44%跑赢沪指 证券时报·数据宝对上一期(7月10日)筹码集中股监测显示，这些股7月1日以来平均上涨4.56%，走势强于 同期沪指表现（上涨3.99%），其中，44%的筹码集中股相对大盘获超额收益。 上期股东户数降逾一 ...

Core Insights - 26 companies listed on the ChiNext board have released their performance forecasts for the first half of the year, with 19 companies expecting profit increases, representing 73.08% of the total [1] - The overall proportion of companies reporting positive forecasts is 80.77%, with 2 companies expecting profits and 1 company forecasting losses [1] Performance Forecast Summary - Among the companies with positive forecasts, 7 are expected to see net profit growth exceeding 100%, while 4 companies anticipate growth between 50% and 100% [1] - Han Yu Pharmaceutical is projected to have the highest net profit growth, with a median increase of 1567.36% [1] - Other notable companies include Chuanjin Nuo and Longyuan Technology, with expected net profit growth of 167.27% and 137.44% respectively [1] Company Performance Highlights - The following companies are highlighted for their significant expected profit increases: - Han Yu Pharmaceutical (Code: 300199) - Expected net profit growth: 1567.36%, Latest closing price: 18.24, Year-to-date change: 41.51%, Industry: Pharmaceutical [1] - Chuanjin Nuo (Code: 300505) - Expected net profit growth: 167.27%, Latest closing price: 19.95, Year-to-date change: 40.94%, Industry: Basic Chemicals [1] - Longyuan Technology (Code: 300105) - Expected net profit growth: 137.44%, Latest closing price: 8.11, Year-to-date change: 7.79%, Industry: Environmental Protection [1] - Other companies with notable growth include Chenguang Biotech, Feirongda, Boteng Co., and Huizhong Co. [1]

Group 1 - A total of 18 companies listed on the ChiNext board have released their performance forecasts for the first half of the year, with 13 companies expecting profit increases, 1 company expecting to turn a profit, 1 company expecting a profit decrease, and 1 company expecting a loss [1][3] Group 2 - The performance forecast details include various companies with significant expected profit growth, such as: - Hanyu Pharmaceutical (300199) with a projected profit increase of 1567.36% [2] - Chuanjin Nuo (300505) with a projected profit increase of 167.27% [2] - Chenguang Biotech (300138) with a projected profit increase of 117.36% [2] - Huizhong (300371) with a projected profit increase of 100.00% [2] - Taotao Automotive (301345) with a projected profit increase of 84.08% [2] Group 3 - Companies with performance forecasts indicating a decrease or loss include: - Zairun (301636) with a projected profit decrease of 5.43% [2] - Yuyou Green Energy (301590) with a projected profit decrease of 6.57% [2] - Juguang (300203) with a projected loss of 205.37% [2]

Group 1 - The company Huizhong Co., Ltd. experienced a 20cm limit-up in stock price [1]

Group 1 - Dazhihui reported that its daily operations are normal and there are no significant changes [4] - Jinchengzi announced that revenue from laser 3D printing control systems will account for less than 2% of total revenue in 2024 [5][6] - Bayi Shikong is expanding into edge computing business [8] - Zhengfan Technology plans to acquire 62.23% stake in Hanjing Semiconductor [10] - Dayang Electric is planning to issue H-shares and list on the Hong Kong Stock Exchange [18] Group 2 - Haitong Development intends to use up to $65 million to purchase dry bulk carriers [2] - Juhua Co. expects a net profit of 1.97 billion to 2.13 billion yuan for the first half of 2025, a year-on-year increase of 136% to 155% [3] - Dajin Heavy Industry anticipates a net profit of 510 million to 570 million yuan for the first half of 2025, a year-on-year increase of 193.32% to 227.83% [11] - Yatai Co. expects a net profit of 190 million to 210 million yuan for the first half of 2025, a year-on-year increase of 81.97% to 101.13% [12] - Huizhong Co. expects a net profit of 39.98 million to 42.03 million yuan for the first half of 2025, a year-on-year increase of 95% to 105% [13]

汇中仪表股份有限公司 2025 年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间 证券代码：300371 证券简称：汇中股份 公告编号：2025-057 预计的业绩：□亏损 □扭亏为盈 √同向上升 □同向下降 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 营业收入 | 万元 营收：20,399.82 万元–21,806.70 | 营收 14,068.84 万元 | | | 比上年同期增长：45%-55% | | | 归属于上市公司股东的净利润 | 盈利：3,997.62 万元–4,202.62 万元 | 盈利 2,050.06 万元 | | | 比上年同期增长：95%-105% | | | 归属于上市公司股东的扣除非 | 盈利：3,514.09 万元–3,677.54 万元 | 盈利 1,634.46 万元 | | 经常性损益后的净利润 | 比上年同期增长：115%-125% | | 二、业绩预告预审计情况 本次业绩预告的相关财务数据未经注册会计师审计。 三、业绩 ...

Group 1 - The company Huizhong Co., Ltd. (stock code: 300371) announced an expected revenue of 204 million to 218 million yuan for the period from January 1, 2025, to June 30, 2025, representing a growth of 45% to 55% compared to the same period last year, which was 141 million yuan [1] - The net profit attributable to shareholders of the listed company is expected to be between 39.9762 million and 42.0262 million yuan, an increase of 95% to 105% compared to the same period last year, which was 20.5006 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 35.1409 million and 36.7754 million yuan, reflecting a growth of 115% to 125% compared to the same period last year, which was 16.3446 million yuan [1]

Core Viewpoint - The company has approved the use of idle funds to purchase financial products to enhance short-term capital efficiency and increase returns, with a total limit of 600 million yuan for the year [1]. Group 1: Approval and Investment Limits - The company held board and supervisory meetings to approve the use of idle funds for financial product investments, with a maximum investment limit of 600 million yuan [1]. - Individual investment in any financial product is capped at 100 million yuan, with investment periods not exceeding twelve months [1]. Group 2: Progress of Financial Product Investments - The company has made several investments in structured deposits with various banks, including: - 15 million yuan with China Merchants Bank, expected annual return of 1.5%-2.00%, maturing on December 25, 2025 [2]. - 28 million yuan with CITIC Bank, expected annual return of 1.05%-2.07%, maturing on August 13, 2025 [2]. - Additional investments include amounts of 25 million yuan, 30 million yuan, and 20 million yuan with similar expected returns and maturity dates [2]. Group 3: Impact on Daily Operations - The investment in low-risk financial products is designed to ensure that daily operations and capital safety are maintained, without affecting the company's cash flow needs [4]. - The expected returns from these investments are anticipated to enhance the overall performance of the company and safeguard shareholder interests [4]. Group 4: Historical Investment Overview - In the past twelve months, the company and its subsidiaries have engaged in various financial product investments, with amounts ranging from 15 million yuan to 4 million yuan, all yielding positive returns [4][5][6]. - The historical investments include structured deposits with expected annual returns between 1.05% and 2.35% [4][5][6].

代码：300371 证券简称：汇中股份 公告编号：2025-056 汇中仪表股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、购买理财产品审批情况 汇中仪表股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开了第五 届董事会第十八次会议、第五届监事会第十三次会议，2025 年 5 月 16 日召开 2024 年年度股东大会审议通过了《关于使用自有闲置资金购买理财产品的议案》。为 提高资金短期使用效率，增加公司收益，根据公司资金使用情况，在不影响公司 正常经营所需流动资金的情况下，同意公司使用全年累计额度不超过 60,000 万 元的自有闲置资金购买理财产品，其中单个理财产品的投资额度不超过 10,000 万元。期限自 2024 年年度股东大会审议通过之日起至 2025 年年度股东大会召开 之日止，单个理财产品的投资期限不超过十二个月，同时授权公司董事长在该额 度范围内行使投资决策权，并签署相关法律文件。详见公司 2025 年 4 月 18 日于 中国证监会指定网站巨潮资讯网（www. ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]